These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32282032)

  • 1. Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.
    Acanfora D; Ciccone MM; Scicchitano P; Acanfora C; Casucci G
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):135-136. PubMed ID: 32282032
    [No Abstract]   [Full Text] [Related]  

  • 2. Sacubitril/valsartan in COVID-19 patients: the need for trials.
    Acanfora D; Ciccone MM; Scicchitano P; Acanfora C; Casucci G
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):253-254. PubMed ID: 32369103
    [No Abstract]   [Full Text] [Related]  

  • 3. The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19.
    Bellis A; Mauro C; Barbato E; Trimarco B; Morisco C
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33203141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.
    Mann DL; Greene SJ; Givertz MM; Vader JM; Starling RC; Ambrosy AP; Shah P; McNulty SE; Mahr C; Gupta D; Redfield MM; Lala A; Lewis GD; Mohammed SF; Gilotra NA; DeVore AD; Gorodeski EZ; Desvigne-Nickens P; Hernandez AF; Braunwald E;
    JACC Heart Fail; 2020 Oct; 8(10):789-799. PubMed ID: 32641226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neprilysin Inhibitor-Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice.
    Zhang H; Liu G; Zhou W; Zhang W; Wang K; Zhang J
    Sci Rep; 2019 Apr; 9(1):6509. PubMed ID: 31019233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
    Dargad RR; Prajapati MR; Dargad RR; Parekh JD
    Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S102-S110. PubMed ID: 30122239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan).
    Petramala L; Letizia C
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):252. PubMed ID: 32352509
    [No Abstract]   [Full Text] [Related]  

  • 9. Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice.
    Esser N; Schmidt C; Barrow BM; Cronic L; Hackney DJ; Mongovin SM; Hogan MF; Templin AT; Castillo JJ; Hull RL; Zraika S
    Front Endocrinol (Lausanne); 2022; 13():888867. PubMed ID: 35733766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension.
    Li W; Gong M; Yu Q; Liu R; Chen K; Lv W; Yao F; Xu Z; Xu Y; Song W; Jiang Y
    J Clin Hypertens (Greenwich); 2022 Apr; 24(4):449-456. PubMed ID: 35253964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
    Lillyblad MP
    Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angioedema Spotlight: A Closer Examination of Sacubitril/Valsartan Safety Results.
    Owens RE; Oliphant CS
    J Am Board Fam Med; 2017; 30(4):556-557. PubMed ID: 28720639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/Valsartan: potential treatment for paediatric heart failure.
    Das BB; Scholl F; Vandale B; Chrisant M
    Cardiol Young; 2018 Sep; 28(9):1077-1081. PubMed ID: 29979147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF.
    Docherty KF; Vaduganathan M; Solomon SD; McMurray JJV
    JACC Heart Fail; 2020 Oct; 8(10):800-810. PubMed ID: 33004114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.
    Pfau D; Thorn SL; Zhang J; Mikush N; Renaud JM; Klein R; deKemp RA; Wu X; Hu X; Sinusas AJ; Young LH; Tirziu D
    Sci Rep; 2019 Apr; 9(1):5791. PubMed ID: 30962467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia.
    Fuzaylova I; Lam C; Talreja O; Makaryus AN; Ahern D; Cassagnol M
    J Pharm Pract; 2020 Oct; 33(5):696-699. PubMed ID: 30776953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacubitril/valsartan and B-type natriuretic peptide value: recalculating route.
    Abellas-Sequeiros M; Del Prado Díaz S; Del Rey JM; Alonso-Salinas GL; Zamorano JL
    Eur J Heart Fail; 2020 Jan; 22(1):162-163. PubMed ID: 31410947
    [No Abstract]   [Full Text] [Related]  

  • 18. Activation of GLP-1 receptor signalling by sacubitril/valsartan: Implications for patients with poor glycaemic control.
    Mahtani K; Patel B; Wang B; Barron A
    Int J Cardiol; 2022 Nov; 367():81-89. PubMed ID: 35944765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects.
    Akahori M; Ayalasomayajula S; Langenickel T; Pal P; Zhou W; Sunkara G
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):407-416. PubMed ID: 27324506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes.
    Wewer Albrechtsen NJ; Møller A; Martinussen C; Gluud LL; Rashu EB; Richter MM; Plomgaard P; Goetze JP; Kjeldsen S; Hansen LH; Gustafsson F; Deacon CF; Holst JJ; Madsbad S; Bojsen-Møller KN
    Diabetes Obes Metab; 2022 Oct; 24(10):2017-2026. PubMed ID: 35676803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.